FDA Clears Opsumit for Pulmonary HTN

FDA Clears Opsumit for Pulmonary HTN

The 10-mg once daily dose approved by the FDA reduced the composite risk of death, atrial septostomy, lung transplantation, initiation of intravenous or subcutaneous prostanoids, or worsening PAH by 45% compared with placebo in the trial. The higher 

3
Like
Save

Comments

Write a comment

*